LicianPro

C4 Therapeutics, Inc. ·

CCCC 8-K 2026-09-25

C4 Therapeutics, Inc. (CCCC) 8-K dated 2026-09-25 — accession 0001628280-26-063497.

C4 Therapeutics, Inc. (CCCC) is a biotechnology company listed on US.

C4 Therapeutics, Inc. filed a 8-K on 2026-09-25. Accession 0001628280-26-063497.

This 8-K covers: Reg FD disclosure (Item 7.01), Other events (Item 8.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported CCCC revenue for 2025-12-31 was $35.9M. Net income was -$105.0M. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. CCCC currently screens at market cap $425.7M.

Not investment advice. The CCCC SEC hub lists recent forms. The stock page is the research view.

Open on SEC EDGAR

These filings as JSON? API free 100/day

Lician Pro $19.99/mo or $149/yr